Menüü

Otsi

Mouse mAb to human Ribonuclease 7 (clone 4F9)

Mouse mAb to human Ribonuclease 7 (clone 4F9)
               

Figure 1.Western Blot analysis of RNase 7 antibody 4F9. Human RNase 7 was expressed by CHOEBNALT85 cell line. 10 µl of cell culture supernatant was loaded per line. Line 1. Prestained Protein Ladder, Naxo 8003; Line 2. non-reduced conditions; Line 3. Reduced conditions

     

Mouse mAb to human Ribonuclease 7 (clone 4F9)

Figure 2.Immunohistochemistry analysis of of RNase 7 antibody 4F9. Analysis was performed using paraffin-embedded human skin tissue sample. Anti-RNase 7 antibody 4F9 1:500 was used as primary antibody. Biotinylated anti-mouse antibody was used as secondary antibody. Streptavidin-HRP conjugate was used for visualization

Select volume:

Quantity:

€ 2307

Catalogue #

408-100

Name

Mouse mAb to human Ribonuclease 7 (clone 4F9)

Target

Human Ribonuclease 7

Target Description

Recombinant human RNase 7 protein produced by CHO-based Icosagen Cell factory Ltd. proprietary suspension cell line

Alternative Names

RNase 7, SAP-2 (Skin-derived antimicrobialprotein 2)

Uniprot ID

Q9H1E1

Clonality

Mouse monoclonal

Clone

4F9

Class

mIgG1

Reactivity

Human Ribonuclease7

Application

ELISA,WB in non-reduced conditions, IHC, IF

Protocol

Monoclonal antibody optimal dilution has to be established practically for each antigen and assay format

ELISA:

0,02-0,05 µg/ml

WB:

0,5-1 µg/ml

IF:

1-10 µg/ml

IHC:

5-20 µg/ml

Purification

Protein G purification

Buffer

PBS pH 7.4, with 0.1 % sodium azide

Shipping

This product is shipped in non-frozen liquid form in ambient conditions

Storage

Store at -20 °C to -70 °C upon receipt. Divide antibody into aliquots prior usage. Avoid multiple freeze-thaw cycles as product degradation may result

Background

RNase 7 exhibit potent ribonuclease activity and thus may contribute to the well-known ribonuclease activity of human skin. RNase 7 revealed broad spectrum antimicrobial activity against many pathogenic microorganisms and remarkably potent activity (lethal dose of 90% < 30 nm) against a vancomycin-resistant Enterococcus faecium (Harder and Schröder, 2002)

This product is for research use only

TECHNICAL ASSISTANCE

Please refer any technical questions to

technical.support@icosagen.com

Meie asukoht

Ameerika Ühendriikide kontor

77 Geary St. 5th Floor
San Francisco, CA 94108
+1 415 548 6625

Eesti kontor

Eerika tee 1
Õssu, Kambja vald
Tartu maakond 61713
Estonia
+372 737 7070
Shopping Cart